Genetically Engineered Mouse Models: Closing the Gap between Preclinical Data and Trial Outcomes

被引：93

作者：

Singh, Mallika ^{[1
]}

Murriel, Christopher L. ^{[1
]}

Johnson, Leisa ^{[1
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

来源：

CANCER RESEARCH | 2012年 / 72卷 / 11期

关键词：

GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; HUMAN TUMOR XENOGRAFTS; PANCREATIC-CANCER; PATHWAY ACTIVATION; PLUS GEMCITABINE; CLINICAL-TRIALS; KRAS; CHEMOTHERAPY; EXPRESSION;

D O I：

10.1158/0008-5472.CAN-11-2786

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The high failure rate of late-stage human clinical trials, particularly in oncology, predicates the need for improved translation of preclinical data from mouse tumor models into clinical predictions. Genetically engineered mouse models (GEMM) may fulfill this need, because they mimic spontaneous and autochthonous disease progression. Using oncogenic Kras-driven GEMMs of lung and pancreatic adenocarcinoma, we recently showed that these models can closely phenocopy human therapeutic responses to standard-of-care treatment regimens. Here we review the successful preclinical application of such GEMMs, as well as the potential for discovering predictive biomarkers and gaining mechanistic insights into clinical outcomes and drug resistance in human cancers. Cancer Res; 72(11); 2695-700. (C)2012 AACR.

引用

收藏

页码：2695 / 2700

页数：6

相关论文

共 47 条

[1]

[Anonymous], J CLIN ONCOL S

[2] The patterns and dynamics of genomic instability in metastatic pancreatic cancer [J].

Campbell, Peter J. ;

Yachida, Shinichi ;

Mudie, Laura J. ;

Stephens, Philip J. ;

Pleasance, Erin D. ;

Stebbings, Lucy A. ;

Morsberger, Laura A. ;

Latimer, Calli ;

McLaren, Stuart ;

Lin, Meng-Lay ;

McBride, David J. ;

Varela, Ignacio ;

Nik-Zainal, Serena A. ;

Leroy, Catherine ;

Jia, Mingming ;

Menzies, Andrew ;

Butler, Adam P. ;

Teague, Jon W. ;

Griffin, Constance A. ;

Burton, John ;

Swerdlow, Harold ;

Quail, Michael A. ;

Stratton, Michael R. ;

Iacobuzio-Donahue, Christine ;

Futreal, P. Andrew .

NATURE, 2010, 467 (7319) :1109-1113

[3] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J].

Cappuzzo, Federico ;

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Szczesna, Aleksandra ;

Juhasz, Erzsebet ;

Esteban, Emilio ;

Molinier, Olivier ;

Brugger, Wolfram ;

Melezinek, Ivan ;

Klingelschmitt, Gaelle ;

Klughammer, Barbara ;

Giaccone, Giuseppe .

LANCET ONCOLOGY, 2010, 11 (06) :521-529

[4] Efficacy of anti-cancer agents in cell lines versus human primary tumour tissue [J].

Cree, Ian A. ;

Glaysher, Sharon ;

Harvey, Alan L. .

CURRENT OPINION IN PHARMACOLOGY, 2010, 10 (04) :375-379

[5] Primary human tumor xenografted models ('tumorgrafts') for good management of patients with cancer [J].

Decaudin, Didier .

ANTI-CANCER DRUGS, 2011, 22 (09) :827-841

[6] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].

Eberhard, DA ;

Johnson, BE ;

Amler, LC ;

Goddard, AD ;

Heldens, SL ;

Herbst, RS ;

Ince, WL ;

Jänne, PA ;

Januario, T ;

Johnson, DH ;

Klein, P ;

Miller, VA ;

Ostland, MA ;

Ramies, DA ;

Sebisanovic, D ;

Stinson, JA ;

Zhang, YR ;

Seshagiri, S ;

Hillan, KJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909

[7] Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers [J].

Engelman, Jeffrey A. ;

Chen, Liang ;

Tan, Xiaohong ;

Crosby, Katherine ;

Guimaraes, Alexander R. ;

Upadhyay, Rabi ;

Maira, Michel ;

McNamara, Kate ;

Perera, Samanthi A. ;

Song, Youngchul ;

Chirieac, Lucian R. ;

Kaur, Ramneet ;

Lightbown, Angela ;

Simendinger, Jessica ;

Li, Timothy ;

Padera, Robert F. ;

Garcia-Echeverria, Carlos ;

Weissleder, Ralph ;

Mahmood, Umar ;

Cantley, Lewis C. ;

Wong, Kwok-Kin .

NATURE MEDICINE, 2008, 14 (12) :1351-1356

[8] Mouse models of advanced spontaneous metastasis for experimental therapeutics [J].

Francia, Giulio ;

Cruz-Munoz, William ;

Man, Shan ;

Xu, Ping ;

Kerbel, Robert S. .

NATURE REVIEWS CANCER, 2011, 11 (02) :135-141

[9] Maximizing mouse cancer models [J].

Frese, Kristopher K. ;

Tuveson, David A. .

NATURE REVIEWS CANCER, 2007, 7 (09) :645-658

[10] Molecular markers of pancreatic cancer:: development and clinical relevance [J].

Fry, Lucia C. ;

Moenkemueller, Klaus ;

Malfertheiner, Peter .

LANGENBECKS ARCHIVES OF SURGERY, 2008, 393 (06) :883-890

← 1 2 3 4 5 →